Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial
Authors' conclusion
During long-term follow-up through 10 years, the annual risks of ID-TLR and definite ST significantly decreased beyond 5 years after first-generation DES implantation.
Study context
- Population
- All-comers undergoing coronary revascularization with first-generation drug-eluting stents (DES)895 (88.4%) complete 10-year follow-up
- Participants
- 1,012 participants
- Comparison
- Sirolimus-eluting stent (SES) vs paclitaxel-eluting stent (PES); annual risk 1–5 years vs 5–10 years
- SESn = 503
- PESn = 509reference
Methodological detailsall-comers, 10-year extended follow-up
- All-comers
- 10-year extended follow-up
Primary result
As reported in the abstract
Annual risk of ID-TLR and definite ST, 5–10 years vs 1–5 years · 10 years
5–10 years vs 1–5 yearsHazard ratio (95% CI)P value
ID-TLR: 1.8% vs. 0.7%/year
0.36(0.21–0.62)
P < 0.001Definite ST: 0.67% vs. 0.23%/year
0.31(0.13–0.75)
P = 0.01- Ischaemia-driven target lesion revascularization (ID-TLR) rate at 1, 5, 10 years
- 8.1%, 14.6% and 17.7%
- Stent thrombosis (ST) rate at 1, 5, 10 years
- 1.9%, 4.5% and 5.6%
Further findings
Major adverse events (cardiac death, MI, ID-TLR) · 10 years
P = 0.72
Original publication
Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial. Eur Heart J. Published 30 August 2016. doi:10.
Summarised from the published abstract; every number is checked against it